Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Rev Mal Respir ; 31(7): 628-31, 2014 Sep.
Artigo em Francês | MEDLINE | ID: mdl-25239586

RESUMO

INTRODUCTION: Erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), is a targeted therapy used in first, second or third line treatment of non-small cell lung carcinoma. Several cutaneous toxicities after the use of EGFR-TKI are well-described. OBSERVATION: After 13 days of erlotinib treatment, an 82-year-old man, diagnosed with squamous cell lung carcinoma, developed an acneiform rash in parallel with hand-foot syndrome (HFS). This led to the interruption of his treatment because of the patient's distress. However, for the first time and after a total recovery of the toxidermia, we reintroduced the therapy at very low doses without any HFS recurrence being observed. DISCUSSION: The HFS is a dose-dependent toxidermia appearing within the first week following administration of the triggering cytotoxic agents (chemotherapies or target therapies). It appears that a specific pathogenic mechanism exists for each cytotoxic agent triggering the skin damage, resulting in different clinical presentations. A major aspect of HFS treatment involves the reduction or withdrawal of the treatment. CONCLUSIONS: We describe what is to our knowledge, the third case of erlotinib-induced HFS, a new secondary undesirable skin pathology for which, currently, exist few direct causal explanations or drug monitoring. This observation highlights the importance of broadening our knowledge of the exact mechanisms linking EGFR-TKI to the appearance of HFS in order to optimize treatment.


Assuntos
Síndrome Mão-Pé/tratamento farmacológico , Síndrome Mão-Pé/etiologia , Inibidores de Proteínas Quinases/administração & dosagem , Inibidores de Proteínas Quinases/efeitos adversos , Quinazolinas/administração & dosagem , Quinazolinas/efeitos adversos , Idoso de 80 Anos ou mais , Carcinoma de Células Escamosas/tratamento farmacológico , Cloridrato de Erlotinib , Humanos , Neoplasias Pulmonares/tratamento farmacológico , Masculino , Síndrome de Pancoast/tratamento farmacológico , Retratamento
2.
Acta Clin Belg ; 69(2): 146-8, 2014 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-24724761

RESUMO

A 19-year-old man was admitted with acute dyspnoea. Physical examination revealed subcutaneous emphysema in the cervical and thoracic area. This was further confirmed by the total body computed tomography that also demonstrated mediastinal emphysema. Epidural pneumatosis of the thoracis spine was also evident. There was no history of trauma, but well of a recent oral ecstasy consumption during a techno rave party, associated with intense dancing and jumping. Clinical course was favourable with conservative therapy.


Assuntos
Espaço Epidural/patologia , Enfisema Mediastínico/induzido quimicamente , N-Metil-3,4-Metilenodioxianfetamina/efeitos adversos , Adulto , Dispneia/induzido quimicamente , Espaço Epidural/efeitos dos fármacos , Humanos , Masculino , Adulto Jovem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA